NCT06455826 - MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Retinitis Pigmentosa 11Retinal DegenerationEye DiseasesRetinal DiseaseRetinal Dystrophies

Interventions

DRUG

VP-001

A Phase 1 Open-Label, Multiple Ascending Dose Study of VP-001 in Participants with Confirmed PRPF31 Mutation- Associated Retinal Dystrophy

Trial Locations (5)

RECRUITING

University of Florida Health, Jacksonville

RECRUITING

University of Michigan Kellogg Eye Center, Ann Arbor

RECRUITING

Retina Foundation of the Southwest, Dallas

RECRUITING

Baylor College of Medicine- Alkek Eye Center, Houston

RECRUITING

Oregon Health and Science University - Casey Eye Institute, Portland